Study of Tofacitinib In Refractory Dermatomyositis (STIR): An open label pilot study of 10 patients

OBJECTIVES: This open-label 12-week study was conducted to evaluate the efficacy and safety of tofacitinib, a JAK inhibitor, in active, treatment-refractory dermatomyositis. METHODS: Tofacitinib was given as 11 mg XR daily to 10 subjects. All subjects underwent complete washout of all steroid sparin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Rheumatol
Autors principals: Paik, Julie J., Casciola-Rosen, Livia, Shin, Joseph Yusup, Albayda, Jemima, Tiniakou, Eleni, Leung, Doris G., Gutierrez-Alamillo, Laura, Perin, Jamie, Florea, Liliana, Antonescu, Corina, Leung, Sherry G., Purwin, Grazyna, Koenig, Andrew, Christopher-Stine, Lisa
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084900/
https://ncbi.nlm.nih.gov/pubmed/33258553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41602
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars